SCHEMBL7217491

SCHEMBL7217491

COC(=O)C(O)Cc1ccc(NC(=O)OCc2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.57
TP53 P04637 2/20 0.53
MAPT P10636 2/20 0.53
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
KDM1A O60341 2/20 0.52
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
MGLL Q99685 1/20 0.51
ROCK2 O75116 1/20 0.51
RCOR1 Q9UKL0 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
ALOX15 P16050 1/20 0.50
PTGDR2 Q9Y5Y4 2/20 0.49
TSHR P16473 1/20 0.49
ATM Q13315 1/20 0.49
HDAC8 Q9BY41 1/20 0.48
LTA4H P09960 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22402969 0.90 SMN1; SMN2 (0.59) POLBTP53MAPTNPC1RAB9A
SCHEMBL21552129 0.90 SMN1; SMN2 (0.59) POLBTP53MAPTNPC1RAB9A
SCHEMBL7217283 0.89 POLB (0.59) POLBTP53MAPTNPC1RAB9A
SCHEMBL28476992 0.84 SMN1; SMN2 (0.51) POLBMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL3980617 0.83 KMT2A (0.55) POLBMAPTNPC1RAB9AALDH1A1
SCHEMBL180159 0.83 KMT2A (0.55) POLBMAPTNPC1RAB9AALDH1A1
SCHEMBL979240 0.83 KMT2A (0.55) POLBMAPTNPC1RAB9AALDH1A1
SCHEMBL15947583 0.81 POLB (0.50) POLBTP53MAPTNPC1RAB9A
SCHEMBL23917849 0.80 ALDH1A1 (0.69) POLBTP53MAPTNPC1RAB9A
SCHEMBL592715 0.80 POLB (0.66) POLBTP53MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531604-B2 Useful as medicines having an osteogenesis promoting effect and chondrogensis promoting effect. TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-03-11 US disclosed
US-20020128308-A1 Benzothiepine derivatives, their production and use YASUMA TSUNEO (JP) 2002-09-12 US disclosed
US-6355672-B1 BONE DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-03-12 US disclosed
EP-1103552-A1 BENZOTHIEPIN DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128308-A1 Benzothiepine derivatives, their production and use APP, BMP1, BACE1 POLB 3851/4885TP53 2752/4885MAPT 331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.